The AbbVie Patient Assistance Foundation provides AbbVie medications at no cost to patients with financial difficulty who may (or may not) have or qualify for prescription medication benefits through private insurance or government-funded programs.
Patients who meet Akrimax’s income guidelines may be eligible to receive Tirosint for free. Qualifying patients are eligible for free medication for 1 year and must then reapply to the program.
With this savings card, patients are responsible for the first $35 and will receive up to $35 off their out-of-pocket expenses. Insured and cash-paying patients are eligible for the savings card. Medicare and Medicaid patients are not eligible for the program.
Patients who cannot afford the cost of Trelstar and meet other eligibility requirements may qualify for free medication. Eligible applicants will be enrolled for 12 months, and a 90-day supply of medication will be immediately shipped to the physician. Medicare Part D applicants must have been denied Low-Income Subsidy and will only be enrolled until the end of the calendar year.
Uninsured patients who meet certain financial criteria may be eligible to receive Injectafer free of charge.
Enrolling in this program gives patients drug reimbursement assistance, as well as referrals for transportation, lodging, and copay assistance. For patients with Medicare or Medicaid, Amgen Assist 360 provides referrals to independent nonprofit foundations that can help pay for their Amgen medication.
The Amgen FIRST STEP program helps qualified commercially insured patients cover their deductible, coinsurance, or copay out-of-pocket costs.
Amgen’s Safety Net Foundation is a nonprofit patient assistance program designed to assist patients who are uninsured, with limited or no financial resources. Program eligibility is based on US residency, insurance status, and income requirements.
Arbor is pleased to offer prescription assistance for patients who qualify through the Arbor Pharmaceuticals Patient Assistance Program. Patients who meet the eligibility requirements and wish to be considered for participation must complete and submit a Patient Assistance Program Application.
The ARIAD Patient Access and Support (ARIAD PASS) program helps providers and patients afford their Ariad treatment.
Xtandi Support Solutions helps providers and patients understand patients’ cost-sharing obligations that can reduce the cost of Xtandi for eligible patients. The program includes the Astellas Access Program, which provides free Xtandi to patients who have no health insurance and who qualify for enrollment based on their insurance status and household income, as well as the Xtandi Patient Savings Program for insured patients who have private health insurance but who may not be able to pay their out-of-pocket costs.
AstraZeneca’s Access 360 program is designed to streamline access to the company’s drugs through a variety of support options. Access 360 provides patients, their caregivers and family, and providers with affordability and reimbursement support in obtaining their medications.
The AZ&Me AstraZeneca Prescription Savings Program provides AstraZeneca medications at no cost to individuals without health insurance and to Medicare Part D beneficiaries. This program provides AstraZeneca medications to low-income patients through qualifying facilities, such as disproportionate-share hospitals, community health centers, community free clinics, central-fill pharmacies, and charitable pharmacy programs.
The $0 Co-Pay Program allows patients to fill their prescription with no out-of-pocket costs for eligible, commercially insured patients. Patients can receive up to $25,000 in savings, with no monthly maximum.
This free support program provides patients with financial assistance options and with information about therapy. This program supplies patients with Medicare, Medicaid, and military insurance information about financial assistance options that may be available through independent charitable organizations, and qualified underinsured or uninsured patients may be eligible for up to 12 months of free drugs.
Xofigo Access Services provides Xofigo free of charge to eligible patients who are uninsured or who are insured but do not have coverage for Xofigo. Patients with private commercial insurance may also be eligible for copay assistance.
This program is designed to assist with out-of-pocket copays or coinsurance requirements for eligible, commercially insured patients prescribed Bristol-Myers Squibb medications, per FDA-approved indications.
This foundation helps US residents in need obtain Boehringer Ingelheim medications free of charge. Patients must meet certain financial criteria to be eligible for assistance.
Solutions Plus provides financial assistance for Boehringer Ingelheim medicines to patients who meet income requirements.
Through its Access Support Program, Bristol-Myers Squibb offers a variety of oncology support options for patients receiving outpatient treatment in the United States and Puerto Rico, and, in certain circumstances, the Virgin Islands.
This foundation assists patients who need temporary help paying for BMS medications. To receive temporary help, patients must prove financial hardship and meet other criteria.
For patients with private insurance and an annual household income of up to $100,000, this program can reduce the prescription copay to $0 by providing up to $10,000 per calendar year to cover deductible and copay costs for Celgene medications.
Patients with no insurance or not enough insurance to cover their Celgene medications who meet certain financial criteria may qualify for this program to receive their medication for free.
This program connects patients who have public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.
The Dendreon ON Call program supports eligible, insured patients by covering any combination of cost (copays, coinsurance, or deductibles) to a maximum of $6,000 over 3 Provenge treatments. This program also helps eligible patients with Medicare pay for copays, coinsurance, and deductibles, and patients who are uninsured and who meet certain financial criteria may be able to get Provenge at no cost.
Patients with private insurance who meet the eligibility requirements will pay no more than $10 monthly for out-of-pocket prescription costs for Cabometyx.
This program provides Cabometyx free of charge to qualifying patients who are uninsured or underinsured.
Eligible patients who experience a delay of more than 5 days in the processing or approval of their prescription can receive a 15-day supply of Cabometyx at no cost.
Through Eisai Reimbursement Resources, patients who are prescribed Eisai pharmaceuticals can find drug-specific resources related to coding, coverage, and reimbursement, as well as a variety of patient assistance services. The resources provided by Eisai Reimbursement Services are drug-specific; therefore, patients and providers are encouraged to visit www.eisaireimbursement.com and select their prescribed medication for more information on programs specific to that drug.
The Endo Pharmaceuticals Patient Assistance Program offers free medications to patients who otherwise cannot afford them. Patients must meet financial and other program-specific criteria to be eligible for assistance.
This program benefits patients who are privately insured or uninsured. For patients with insurance coverage and a copay, Forward Science pays the copay amount, resulting in no out-of-pocket costs for the patient. For patients without insurance coverage, the program offers a discounted cash price.
Genentech Access Solutions provides programs and services to help facilitate access to Genentech BioOncology medicines for eligible patients and healthcare professionals. Services include coverage and reimbursement assistance, financial assistance, and resource support, and vary depending on patients’ insurance status.
The Genentech Access to Care Foundation helps patients receive medications for free if they do not have a healthcare plan or have been denied coverage for treatment. Patients must have a household-adjusted income of $100,000 or less annually.
This program has no income requirements for participation. Patients who qualify for this program have a copay of $25. Genentech covers up to $25,000 annually per patient for the cost of this drug.
The Zydelig AccessConnect program provides Zydelig at no charge to eligible patients with no other insurance options.
A simple one-stop solution for patients with oral mucositis or stomatitis, this program allows patients to receive Gelclair bioadherent oral rinse gel within 24 hours of prescription receipt or confirmation. Most insured patients pay $0 out of pocket for 1 month of therapy.
Privately insured and uninsured patients can benefit from this copay program. Patients with private insurance will pay $0 per dose for a 12-month calendar period for Sustol. For uninsured patients, the program will cover $150 per prescription up to $1,800 per calendar year. Patients must reapply after each 12-month period. Sustol can be provided at no cost to patients with financial hardship who meet the program eligibility criteria through the Patient Assistance Program.
IncyteCARES (Connecting to Access, Reimbursement, Education, and Support) is a suite of services provided by Incyte for patients receiving treatment with Jakafi. In addition to patient education, resource support, and helping patients overcome potential insurance barriers, IncyteCARES offers a free medication program, as well as reimbursement and financial assistance options.
Patients with private or commercial prescription insurance may be eligible to receive Jakafi for as little as $25 monthly, not exceeding $25,000 annually, if they qualify.
Privately insured and uninsured patients can use this copay savings card to receive 10 free units of 100-mcg Subsys and/or up to 30 free units of 200 mcg to 1600 mcg of Subsys. Patients will also receive up to $1,000 off each additional prescription of Subsys.
Ipsen Biopharmaceuticals provides several patient services through its IPSEN CARES: Coverage, Access, Reimbursement & Education Support program to patients who are prescribed Somatuline Depot for the treatment of neuroendocrine tumors arising from the gastrointestinal tract or the pancreas. IPSEN CARES facilitates access to Somatuline Depot to patients who are insured, underinsured, or uninsured.
Eligible, privately insured patients pay no more than $5 for a prescription for 12 months, for 13 injections, or for an annual maximum of $20,000 (whichever comes first). For patients with no insurance or whose insurance does not cover Somatuline Depot, the cost may be more than $5 per prescription, and the maximum benefit amount per prescription is $1,666.66, up to the annual maximum of $20,000 in total.
Eligible patients who are experiencing financial hardship, have no insurance coverage, and meet specific medical criteria will receive Somatuline Depot for free.
Janssen CarePath offers one source for patient resources, focused on access, affordability, and treatment support for patients who are prescribed a Janssen cancer medication. The CarePath program also includes patient information about each medication offered, as well as other patient support via the Janssen Learning Center. There are also tools available to help patients stay on track with taking and keeping up with their medication regimens.
For patients who meet the program’s requirements, the JumpStart Patient Assistance program offers Defitelio and Erwinaze free of charge.
The Johnson & Johnson Patient Assistance Foundation assists patients without adequate financial resources and prescription drug coverage in obtaining free medications donated by the operating companies of Johnson & Johnson. There is 1 application for all agents, and patients may receive free medicines for up to 1 year.
Patient Rx Solutions is designed to assist uninsured individuals and those who have no public or private prescription coverage. Kyowa Kirin also offers copay assistance to eligible individuals with private insurance.
PatientOne addresses financial and coverage issues for qualified uninsured, underinsured, and insured patients who are prescribed a Lilly oncology drug. PatientOne can help provide replacement vials for ongoing therapy to qualified uninsured patients who earn up to 500% of the federal poverty level. In addition, PatientOne provides assistance to insured patients whose claims for a Lilly oncology drug have been denied by their insurer. Certain eligibility requirements apply. Approved drug requests are conveniently shipped to the physician’s office.
For patients with private insurance whose household income does not exceed $100,000 or 500% of the federal poverty level, this program provides up to $42,000 annually so that the patient pays no more than $25 per infusion.
The ACT Program and Merck Access Program (MAP) provide free reimbursement support services to help answer questions related to insurance coverage and reimbursement. The ACT Program also refers patients to the Patient Assistance program, which provides certain Merck medicines free of charge to eligible patients who do not have insurance coverage. Many Merck medications are included in this program.
The Merck Co-Pay Assistance Program is available to patients with private health insurance who have been prescribed Keytruda, Intron A for injection, or Sylatron, and meet certain financial requirements.
Uninsured patients who cannot afford to pay for Temodar and have an annual household income of $47,520 or less for individuals, $64,080 or less for couples, or $97,200 or less for a family of 4, may qualify to receive their medication for free.
PROVYDE (Onivyde Access Services) offers patient support services and reimbursement services to facilitate patient access to Onivyde. PROVYDE offers a $0 commercial copay program, a patient assistance program, assistance with insurance verification, and help with referrals to independent, nonprofit organizations for federally insured patients and referrals for travel assistance. The program also supports healthcare providers in submitting claims for Onivyde by contacting the payer to confirm that the claim submission was processed correctly, tracking claims until a decision is rendered and relaying results to the provider, and helping the provider’s office troubleshoot any denied or rejected claims.
This program provides information on coverage, prior authorization, and copay.
For eligible patients with private insurance, the Novartis Oncology Universal Co-Pay Card ensures a prescription copay of no more than $25 monthly for a Novartis medication. Novartis pays the remaining balance until a yearly maximum of $15,000 is met.
The Novartis Patient Assistance Foundation provides assistance to patients who experience financial hardship and who have no third-party insurance coverage for their Novartis medications.
The Novartis Patient Assistance Now Oncology Program offers quick and easy access to information about the many reimbursement and support programs available to patients. Patients with private insurance or without prescription coverage may be eligible to receive copay discount cards on certain medications.
Peak provides resource support and reimbursement programs for patients receiving Sandostatin LAR. This program provides a patient assistance program for low-income and uninsured patients and will send a 30-day supply of medication after patients prequalify by phone.
With this card, privately insured patients new to Tasigna can receive a 30-day initial supply of Tasigna and up to two 30-day refills if insurance coverage for Tasigna has not yet been established. Once insurance coverage is established, patients can use the card and pay $0 copay for their prescription, with a $32,000 maximum benefit annually ($9,600 monthly). For Medicare patients, this offer provides a 3-month (90-day) supply of Tasigna. After the 90-day period, Medicare patients will be responsible for the cost of Tasigna.
This comprehensive reimbursement support service and patient assistance program helps eligible patients access Somavert.
This Pfizer program assists privately insured patients so that their copay is no more than $10 monthly, with a maximum savings benefit of $25,000 yearly.
Patients who are prescribed a Pfizer specialty medicine and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.
Through this program, uninsured patients, regardless of income, will see an estimated savings of 36% to 75% on their medication costs when purchased at a participating retail pharmacy.
Patients with commercial insurance and who meet certain eligibility requirements pay no more than $10 monthly for Imbruvica. Eligible patients prescribed Imbruvica for an FDA-approved indication, and who are experiencing an insurance coverage delay of >5 business days, can receive a free 30-day supply of Imbruvica. Under appropriate circumstances, an additional free 30-day supply of Imbruvica may be provided.
This program is designed to assist financially disadvantaged patients who have no prescription coverage. Eligible patients must have an annual household income at or below 200% of the federal poverty level.
This program offers financial assistance for Ixempra, including a copay program assisting with out-of-pocket copay or coinsurance requirements for eligible, privately insured patients. A patient assistance program is also available for eligible, uninsured patients.
Sandoz One Source offers customized support services for patients prescribed Zarxio, including comprehensive insurance verification; prior authorization support when required; billing and coding information; information on claims tracking, denials, and appeals; and payer policy research. Sandoz One Source also offers financial assistance to eligible patients.
Privately insured patients with out-of-pocket costs exceeding $100 for each Thyrogen kit may be eligible for assistance. This program requires patients to pay $100 of their out-of-pocket costs, and Sanofi Genzyme will cover any additional out-of-pocket costs, up to $1,000 per calendar year.
Patients who are uninsured or underinsured may be eligible to receive up to 2 kits of Thyrogen per calendar year.
Through the Sanofi Foundation for North America, Sanofi Patient Connection provides medications free of charge to patients who have no insurance coverage or who are considered to be functionally uninsured.
Through this program, Seattle Genetics ensures that patients who are uninsured and meet certain financial criteria will be eligible to receive Adcetris at no cost. With this program, assistance begins with a temporary 3-month period.
Spectrum Therapy Access Resources (STAR) includes a copay assistance program to assist privately insured patients (who meet the STAR eligibility criteria) with copay and coinsurance responsibilities related to certain Spectrum medications. In addition, the STAR program provides Spectrum medications free of charge to enrolled patients who meet the income, insurance, and citizenship/residency eligibility criteria.
The Taiho Oncology Patient Support program provides a range of personalized support services for patients who have been prescribed Lonsurf, including access and reimbursement support, specialty pharmacy prescription coordination, copay support, and a patient assistance program, based on their financial needs and insurance coverage.
Takeda Oncology’s Ninlaro 1Point offers comprehensive services that can assist patients with the financial burden and other day-to-day needs associated with Ninlaro treatment, including assisting eligible patients with out-of-pocket costs; helping patients understand their insurance coverage for Ninlaro; providing information about specialty pharmacies that can help patients get Ninlaro; helping patients start therapy as quickly as possible, as directed by their physician; and connecting patients to additional resources, such as legal services, counseling and support programs, emotional support, and transportation assistance.
Takeda Oncology’s Velcade Reimbursement Assistance Program (VRAP) and the Velcade Patient Assistance Program (VPAP) offer a suite of services and resources to practices and eligible patients seeking access to Velcade. Patient services under VRAP and VPAP include financial assistance; navigation through reimbursement processes and concerns; referrals to independent copay foundations; and support and resources for the insured, uninsured, and underinsured.
This foundation offers some medications at no cost to eligible patients who meet certain income and insurance criteria.
Comprehensive Oncology Reimbursement Expertise supports patients and providers through programs for eligible patients treated in the United States who do not have insurance, cannot afford their out-of-pocket copay costs, or need assistance with reimbursement issues.
TOGETHER with TESARO offers solutions to patients for medication access and affordability. Tesaro’s case management team of experts in access and affordability facilitates a seamless process to ensure that patients get the individualized support they need. Currently, the program is offering its services to patients who are prescribed Varubi. TOGETHER with TESARO can offer coverage support, a free first-dose program that provides a single-dose wallet card of Varubi at no cost to patients, and a patient assistance program for eligible uninsured and underinsured patients. Patients may also be eligible for the commercial copay assistance program, which is an independent program that reduces out-of-pocket costs for commercially insured patients and reduces copayments and/or coinsurance to $0 with a $300 per dose cap and no annual maximum allowable benefit. The virtual card can be initiated and utilized by in-office dispensing pharmacies, hospital outpatient clinics, or by the exclusive specialty pharmacy of Tesaro.
Patients who are uninsured or underinsured may qualify to get help with the cost of Eligard. Patients must meet certain financial restrictions.
The Zydelig QuickStart Program gives eligible patients who have an insurance coverage delay of more than 5 business days rapid access to a free, one-time, 30-day supply of Zydelig.